Lupin has launched Hyalgan (sodium hyaluronate), an osteoarthritis drug available in the form of an injectable through leading orthopaedics and physiotherapists across the country. Hyalgan is the original research molecule of the Italian pharma giant FIDIA and is the world leader in hyaluronan and hylan (HA) therapy, marketed in over 60 countries globally.
The drug, which is a natural liquid injected into the knees to relieve pain caused due to osteoarthritis, has been test- marketed by Lupin over the last 6 months across the country. Hyalgan is recommended for patients of stage 1 to 3 of OA to relieve the acute pain associated with it. Hyalgan can also delay the progression of OA when taken regularly as per the schedule, According to a recently concluded survey, the market for osteoarthritis is currently pegged at INR 150 crores. In India OA is the 2nd most prevalent disease in the age group of 25-30 years and affects more than 12% of the population.
Source :www.biginfotech.in
The drug, which is a natural liquid injected into the knees to relieve pain caused due to osteoarthritis, has been test- marketed by Lupin over the last 6 months across the country. Hyalgan is recommended for patients of stage 1 to 3 of OA to relieve the acute pain associated with it. Hyalgan can also delay the progression of OA when taken regularly as per the schedule, According to a recently concluded survey, the market for osteoarthritis is currently pegged at INR 150 crores. In India OA is the 2nd most prevalent disease in the age group of 25-30 years and affects more than 12% of the population.
Source :www.biginfotech.in
No comments:
Post a Comment